Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 10 results.
User Information
Export Records
  1. 1.   Multiple configurations of EGFR exon 20 resistance mutations after first- and third-generation EGFR TKI treatment affect treatment options in NSCLC
  2. Goldberg, Michael E.; Montesion, Meagan; Young, Lauren; Suh, James; Greenbowe, Joel; Kennedy, Mark; Giaccone, Giuseppe; Akerley, Wallace L.; Dowlati, Afshin; Creelan, Benjamin C.; Hicks, James K.; Hesketh, Paul J.; Kelly, Karen L.; Riess, Jonathan W.; Miller, Vincent A.; Stephens, Philip J.; Frampton, Garrett M.; Ali, Siraj; Gregg, Jeffrey P.; Albacker, Lee A.
  3. PLOS ONE. 2018, NOV 27; 13(11):
  1. 2.   Structural mimicry of CD4 by a cross-reactive HIV-1 neutralizing antibody with CDR-H2 and H3 containing unique motifs
  2. Prabakaran, P.; Gan, J. H.; Wu, Y. Q.; Zhang, M. Y.; Dimitrov, D. S.; Ji, X. H.
  3. Journal of Molecular Biology. 2006, MAR 17; 357(1): 82-99.
  1. 3.   Crystallography and the design of anti-AIDS drugs: Conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors
  2. Das, K.; Lewi, P. J.; Hughes, S. H.; Arnold, E.
  3. Progress in Biophysics and Molecular Biology. 2005, JUN; 88(2): 209-231.
  1. 4.   Evolution of human immunodeficiency virus under selection and weak recombination
  2. Rouzine, I. M.; Coffin, J. M.
  3. Genetics. 2005, MAY; 170(1): 7-18.
  1. 5.   Craniological differentiation between European wildcats (Felis silvestris silvestris), African wildcats (F-s. lybica) and Asian wildcats (F-s. ornata): implications for their evolution and conservation
  2. Yamaguchi, N.; Driscoll, C. A.; Kitchener, A. C.; Ward, J. M.; Macdonald, D. W.
  3. Biological Journal of the Linnean Society. 2004, SEP; 83(1): 47-63.
  1. 6.   Action of Anti-HIV drugs and resistance: Reverse transcriptase inhibitors and protease inhibitors
  2. Imamichi, T.
  3. Current Pharmaceutical Design. 2004 10(32): 4039-4053.
  1. 7.   Getting back on track, or what to do when apoptosis is de-railed - Recoupling oncogenes to the apoptotic machinery
  2. Fearnhead, H. O.
  3. Cancer Biology & Therapy. 2004 3(1): 21-28.
  1. 8.   De novo design and characterization of a helical hairpin eicosapeptide: Emergence of an anion receptor in the linker region
  2. Rudresh; Ramakumar, S.; Ramagopal, U. A.; Inai, Y.; Goel, S.; Sahal, D.
  3. Structure. 2004 12(3): 389-396.
  1. 9.   Dynamics of Simian immunodeficiency virus-specific cytotoxic T- cell responses in tissues
  2. Veazey, R. S.; Lifson, J. D.; Schmitz, J. E.; Kuroda, M. J.; Piatak, M.; Pandrea, I.; Purcell, J.; Bohm, R.; Blanchard, J.; Williams, K. C.; Lackner, A. A.
  3. Journal of Medical Primatology. 2003 32(4-5): 194-200.
  1. 10.   JE-2147: A dipeptide protease inhibitor (PI) that potently inhibits multi-PI-resistant HIV-1
  2. Yoshimura, K.; Kato, R.; Yusa, K.; Kavlick, M. F.; Maroun, V.; Nguyen, A.; Mimoto, T.; Ueno, T.; Shintani, M.; Falloon, J.; Masur, H.; Hayashi, H.; Erickson, J.; Mitsuya, H.
  3. Proceedings of the National Academy of Sciences of the United States of America. 1999 96(15): 8675-8680.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel